

EXHIBIT A

THE CLAIMS WHICH WILL BE PENDING UPON ENTRY OF THE PRESENT AMENDMENT U.S. PATENT APPLICATION NO. 09/500,397

- TECH CENTER 23 3003
- 19. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease a therapeutically effective amount of plasminogen activator effective to increase the amount of angiostatin present in said animal to treat the angiogenic disease.
- 20. The method of Claim 19 further comprising administering a sulfhydryl donor selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.
- 21. The method of Claim 19 wherein an amount of plasmin is also administered to the animal.
- 23. The method of Claim 19 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.
- 24. The method of Claim 19 wherein an amount of plasminogen is also administered to the animal.
- 76. The method of Claim 19 wherein said animal is a human.
- 77. The method of Claim 19 wherein said angiogenic disease is a neoplastic disease.
- 78. The method of Claim 77 wherein the neoplastic disease is a malignant tumor.
- 79. The method of Claim 77 wherein the neoplastic disease is a benign tumor.
- 80. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease a therapeutically effective amount of a plasminogen activator and a sulfhydryl donor effective to increase the amount of angiostatin present in said animal to treat the angiogenic disease.

- 81. The method of Claim 80 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.
- 82. The method of Claim 80 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.
- 83. The method of Claim 80 further comprising administering plasminogen.
- 84. The method of Claim 80 further comprising administering plasmin.
- 85. The method of Claim 80 wherein said animal is a human.
- 86. The method of Claim 80 wherein said angiogenic disease is a neoplastic disease.
- 87. The method of Claim 86 wherein the neoplastic disease is a malignant tumor.
- 88. The method of Claim 86 wherein the neoplastic disease is a benign tumor.
- 89. The method of claim 19 wherein the angiogenic disease is selected from the group consisting of neoplastic diseases including tumors and tumor metastasis; benign tumors including hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyrogenic granulomas; connective tissue disorders including rheumatoid arthritis and atherosclerosis; ocular angiogenic diseases including diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, and rubeosis; cardiovascular diseases; cerebral vascular diseases; diabetes-associated diseases; and immune disorders including chronic inflammation and autoimmunity.
- 90. The method of claim 80 wherein the angiogenic disease is selected from the group consisting of neoplastic diseases including tumors and tumor metastasis; benign tumors including hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyrogenic granulomas; connective tissue disorders including rheumatoid arthritis and atherosclerosis; ocular angiogenic diseases including diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, and rubeosis; cardiovascular diseases; cerebral vascular diseases; diabetes-associated diseases; and immune disorders including chronic inflammation and autoimmunity